The content of this video has been developed by Johnson & Johnson Ltd.  The views and opinions expressed in the animation are not necessarily those of Johnson & Johnson Ltd or MGP Ltd, its advisers, or advertisers.

Overview of presentation

Johnson & Johnson Ltd have drawn upon CPRD data to weigh the cost to the NHS of prescribing emollients for eczema. This data was presented by Dr George Moncrieff and Mr Simon Rowe at the Health Plus Care Johnson & Johnson Ltd sponsored symposium at the ExCeL London, 28th June 2017.

 

Further reading:

  • Simpson EL et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol 2014; 134: 818-823. Available at: www.ncbi.nlm.nih.gov/pubmed/25282563

Profile of speakers

Dr George Moncrieff, GP, Chair of the Dermatology Council for England

Dr George Moncrieff (FRCP FRCGP DCH DRCOG DPD) has been a GP in North Oxfordshire from 1984. He was an external examiner for the Cardiff DPD until 2005 and was the RCGP Dermatology Curriculum Guardian until 2014. He has been the Chair of The Dermatology Council for England since 2014.

Mr Simon Rowe, Senior Commissioning Manager NHS Wakefield Clinical Commissioning Group 

Simon Rowe is a former healthcare researcher that uses insightful and innovate thinking within NHS commissioning to deliver effective and efficient healthcare services. He is employed by the NHS Wakefield Clinical Commissioning Group, where he is the analytics lead and the lead for the improvement of outpatient services.

Disclosure

The content of this presentation has been reviewed, approved and paid for by Johnson & Johnson Ltd.

The speakers served as consultants and received honoraria from Johnson & Johnson Ltd for their contribution to the study.

The views expressed by the individual speakers do not necessarily reflect the views of Johnson & Johnson Ltd.

Dr George Moncrieff has received sponsorship for talks, presentations, projects, advisory board meetings from: Almirall, Bayer, Derma, Galderma, Johnson & Johnson Ltd, La Roche Posay, LEO Pharma, Stiefel, Thornton & Ross and Typharm.

UK/AV/17-10280a(1)a

Date of preparation: January 2018